Bausch + Lomb, Corporation received approval to extend its Lumify eye drop line with a preservative-free formulation a month after the first generic of the brimonidine tartrate OTC switch was approved as B+L litigates to protect its patents for the product.
First Generic Of B+L’s OTC Switch Lumify Approved For Dr. Reddy’s Amid Patent Infringement Battle
Canadian firm received approval from FDA for NDA submitted in May 2023 for Lumify Preservative Free. A month earlier, FDA approved Dr. Reddy's ANDA submitted in July 2021 for an equivalent of Lumify’s formulation, brimonidine tartrate 0.025% ophthalmic solution.
